Combinatorial Drug Strategies for Thyroid Cancer

Martin Read; Katie Brookes; Christopher McCabe

Combinatorial Drug Strategies for Thyroid Cancer

Martin Read^*, Katie Brookes, Christopher McCabe

^*Corresponding author for this work

Metabolism and Systems Science

Research output: Contribution to specialist publication › Featured article

Abstract

The sodium–iodide symporter (NIS) is the sole known conduit of iodide into human cells. Researchers from the University of Birmingham have identified new combinatorial drug strategies to stimulate NIS activity. These findings have potential clinical application for improving radionuclide-based therapies and imaging across multiple cancer settings.

Original language	English
Pages	11-12
Number of pages	2
No.	156
Specialist publication	The Endocrinologist
Publication status	Published - 19 Jun 2025

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

https://www.endocrinology.org/endocrinologist/156-summer-25/Licence: Unspecified

TRANSFORMING CELLULAR IMAGING AND ABLATION STRATEGIES VIA NEW MECHANISTIC UNDERSTANDING OF THE SODIUM IODIDE SYMPORTER
McCabe, C. (Principal Investigator)
Medical Research Council
1/12/24 → 31/05/28
Project: Research Councils

Cite this

@misc{e54fb811c3e04310b0047c3eaab573d1,

title = "Combinatorial Drug Strategies for Thyroid Cancer",

abstract = "The sodium–iodide symporter (NIS) is the sole known conduit of iodide into human cells. Researchers from the University of Birmingham have identified new combinatorial drug strategies to stimulate NIS activity. These findings have potential clinical application for improving radionuclide-based therapies and imaging across multiple cancer settings.",

author = "Martin Read and Katie Brookes and Christopher McCabe",

year = "2025",

month = jun,

day = "19",

language = "English",

pages = "11--12",

journal = "The Endocrinologist",

issn = "1051-2144",

publisher = "Lippincott Williams and Wilkins",

}

TY - GEN

T1 - Combinatorial Drug Strategies for Thyroid Cancer

AU - Read, Martin

AU - Brookes, Katie

AU - McCabe, Christopher

PY - 2025/6/19

Y1 - 2025/6/19

N2 - The sodium–iodide symporter (NIS) is the sole known conduit of iodide into human cells. Researchers from the University of Birmingham have identified new combinatorial drug strategies to stimulate NIS activity. These findings have potential clinical application for improving radionuclide-based therapies and imaging across multiple cancer settings.

AB - The sodium–iodide symporter (NIS) is the sole known conduit of iodide into human cells. Researchers from the University of Birmingham have identified new combinatorial drug strategies to stimulate NIS activity. These findings have potential clinical application for improving radionuclide-based therapies and imaging across multiple cancer settings.

M3 - Featured article

SN - 1051-2144

SP - 11

EP - 12

JO - The Endocrinologist

JF - The Endocrinologist

ER -

Combinatorial Drug Strategies for Thyroid Cancer

Abstract

UN SDGs

Access to Document

Fingerprint

Projects

TRANSFORMING CELLULAR IMAGING AND ABLATION STRATEGIES VIA NEW MECHANISTIC UNDERSTANDING OF THE SODIUM IODIDE SYMPORTER

Cite this